CB2 Insights adds Marc Adelson to its Board alongside David Danziger stepping to Chairman role

– CANADA, Mississauga –  CB2 Insights (CSE: CBII | OTCQB: CBTOF), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real-World Evidence, today announced the addition of Marc Adelson as new Director to its Board as well as the appointment of David Danziger as its new Chairman.

“With the addition of Marc and now with David as our Chairman, we are proud of the diverse strength our Board is taking,” said Prad Sekar, CEO, CB2 Insights. “We are entering an exciting and pivotal time at CB2 as our clinical operations continue to expand and our data asset continues to grow in its value to a large number of stakeholders throughout the traditional healthcare industry.”

Joining the Board of Directors is Marc Adelson, Deputy Chief Legal Officer at New York-based Teladoc, Inc. (NYSE: TDOC). Mr. Adelson has spent nearly a decade with the healthcare technology firm, both in his current role and as Chief Privacy Officer. Teladoc is a telemedicine company that connects over 3,100 licensed healthcare professionals with millions of patients through comprehensive, virtual care.

“I have been a part of leading-edge healthcare delivery and technology companies for quite some time, and I am thrilled to be able to lend my knowledge to CB2 Insights on the Board,” said Adelson. “I immediately recognized how critical CB2’s role is in understanding medical cannabis prescribing and efficacy and am excited to be a part of that evolution.”

The Company also named David Danziger as Chairman of the Board.

Mr. Danziger is SVP, Assurance & National Leader, Public Companies at MNP, one of the largest accounting and business advisory firms in Canada. He brings extensive public market experience and has served as a Director on many public companies listed on the New York Stock Exchange, TSX, TSX Venture, and Canadian Securities Exchange. He is also a member of CPA Ontario’s Practice Inspection Committee. Mr. Danziger has been a Director with CB2 Insights since 2017.

In addition to Danziger, Adelson, and Sekar, the Board’s other Directors include leading medical cannabinoid expert Dr. Danial Schecter, Founder, Chairman and CEO of vertically-integrated licensed producer GTEC Holdings, Norton Singhavon, and CB2 co-founder and Chief Operations Officer, Kash Qureshi.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands have become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information: https://cb2insights.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>